Figure 1.

Overall scheme of the NEXT‐1 molecular‐screening program. (A): Quality control test for molecular tests. (B): Patients for analysis: pancreatic/biliary tract cancer included 28 pancreatic adenocarcinoma patients (*), 11 gall bladder cancer patients, 13 biliary tract cancer patients, and 10 ampulla of Vater cancer patients; others included 21 sarcoma patients, 21 melanoma patients, 4 gastrointestinal stromal tumor patients, 2 duodenal cancer patients, 1 anal squamous cell cancer patient, 1 adenocortical carcinoma patient, 3 patients with metastases of unknown origin, 1 anaplastic astrocytoma patient, 2 small‐bowel cancer patients, and 9 neuroendocrine carcinoma patients (**).

Abbreviations: QC, quality control; FFPE, formalin‐fixed paraffin‐embedded.